1647 To Flex or Not to Flex? A Case of Immune Checkpoint Inhibitor-Induced Colitis

INTRODUCTION: Diarrhea is a frequent and well-recognized adverse effect of checkpoint inhibitor therapy, occurring in up to 30% of patients. Management depends on the severity of the symptoms and endoscopic investigation should not delay treatment. We report a case of a patient with metastatic melanoma who developed severe checkpoint inhibitor-induced colitis responsive to one dose of infliximab, and did not require flexible sigmoidoscopy. CASE...